Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo
Sponsor: Assistance Publique - Hôpitaux de Paris
Summary
The vast majority of serious clinical situations leading to intensive care (septic shock, polytrauma, acute cerebral aggression, major surgery) are characterized by significant systemic inflammation. Recently, the existence of a common immune response pattern to acute aggression has been demonstrated, and with it the existence of a phenomenon known as post-aggressive immunosuppression (PAIS).
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
170
Start Date
2026-01-12
Completion Date
2028-04
Last Updated
2026-01-22
Healthy Volunteers
No
Conditions
Interventions
Interferon Gamma 1-b
interferon gamma-1b 2 X 106 IU, injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)
Placebo
Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)
Locations (2)
Dr de Roquetaillade
Paris, France
Pr Dépret
Paris, France